Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Sotio Biotech Inc.
Erasca, Inc.
Jonsson Comprehensive Cancer Center
Degron Therapeutics Co.
Actym Therapeutics, Inc.
Ikena Oncology
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Columbia University
National Cancer Institute (NCI)
ABM Therapeutics Corporation
MacroGenics
Fore Biotherapeutics
Zhujiang Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Calando Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Rutgers, The State University of New Jersey
Mannkind Corporation